Views & Analysis

Oncology

Antibody drug conjugates – The time is now

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs ca

Oncology

Suffering beyond physical effects: inequalities and taboos i...

In this episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with André Deschamps, formerly president of Europa Uomo, the voice of men with prostate cancer in Europe.

Oncology

Oncotype DX: Breast cancer, genomics, and rethinking the onc...

EXACT Sciences presented ten new pieces of data at the San Antonio Breast Cancer Symposium (SABCS) back in late 2022, highlighting the impact of its precision oncology portfolio on breast c

Oncology

ASCO 2023 – Dr Lalan Wilfong

In the last video from ASCO 2023, we step away from the R&D side to talk about drug costs and payment models.

Oncology

Molecular glues ‘combine best attributes’ of small and large...

As the industry has transitioned much of its R&D expertise into large molecule therapies, an emerging approach could provide a revolutionary treatment tool.

Oncology